SG10201810263QA - Nampt inhibitors and methods - Google Patents
Nampt inhibitors and methodsInfo
- Publication number
- SG10201810263QA SG10201810263QA SG10201810263QA SG10201810263QA SG10201810263QA SG 10201810263Q A SG10201810263Q A SG 10201810263QA SG 10201810263Q A SG10201810263Q A SG 10201810263QA SG 10201810263Q A SG10201810263Q A SG 10201810263QA SG 10201810263Q A SG10201810263Q A SG 10201810263QA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- nampt inhibitors
- ormula
- mula
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102100033223 Nicotinamide phosphoribosyltransferase Human genes 0.000 title 1
- 235000013350 formula milk Nutrition 0.000 abstract 4
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462001905P | 2014-05-22 | 2014-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201810263QA true SG10201810263QA (en) | 2018-12-28 |
Family
ID=53366297
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201810263QA SG10201810263QA (en) | 2014-05-22 | 2015-05-22 | Nampt inhibitors and methods |
SG11201609615UA SG11201609615UA (en) | 2014-05-22 | 2015-05-22 | Nampt inhibitors and methods |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201609615UA SG11201609615UA (en) | 2014-05-22 | 2015-05-22 | Nampt inhibitors and methods |
Country Status (15)
Country | Link |
---|---|
US (2) | US10017523B2 (zh) |
EP (1) | EP3145933B1 (zh) |
JP (1) | JP6580597B2 (zh) |
KR (1) | KR20170005865A (zh) |
CN (1) | CN106661044B (zh) |
AR (1) | AR100588A1 (zh) |
AU (1) | AU2015263980A1 (zh) |
BR (1) | BR112016026905A8 (zh) |
CA (1) | CA2948878A1 (zh) |
IL (1) | IL249086A0 (zh) |
MX (1) | MX2016015298A (zh) |
RU (1) | RU2016150395A (zh) |
SG (2) | SG10201810263QA (zh) |
TW (1) | TW201625641A (zh) |
WO (1) | WO2015179759A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019006778A2 (pt) | 2016-10-18 | 2019-10-15 | Seattle Genetics Inc | Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco |
KR20190141181A (ko) | 2017-04-27 | 2019-12-23 | 시애틀 지네틱스, 인크. | 사차화된 니코틴아미드 아데닌 다이뉴클레오타이드 구제 경로 억제제 콘쥬게이트 |
WO2022109285A1 (en) * | 2020-11-20 | 2022-05-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for inhibiting nicotinamide phosphoribosyltransferase activity |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL153231A0 (en) | 2000-06-28 | 2003-07-06 | Smithkline Beecham Plc | Wet milling process |
AR057570A1 (es) * | 2005-11-14 | 2007-12-05 | Solvay Pharm Gmbh | Derivados de n-sulfamoil-n'-benzopiranopiperidinas espirocondensadas, composiciones farmaceuticas que los comprenden, un procedimiento para su preparacion y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por las isoenzimas anhidrasas carbonicas subtipos ii y/o |
WO2007088462A1 (en) * | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
WO2012077655A1 (ja) * | 2010-12-07 | 2012-06-14 | 塩野義製薬株式会社 | Gpr119アゴニスト活性を有するスピロ誘導体 |
CA2850394C (en) * | 2011-10-12 | 2019-05-21 | University Health Network | Indazole compounds as kinase inhibitors and method of treating cancer with same |
MX348311B (es) * | 2011-11-11 | 2017-06-06 | Abbvie Inc | Inhibidores nampt. |
US9193723B2 (en) * | 2012-05-11 | 2015-11-24 | Abbvie Inc. | NAMPT inhibitors |
-
2015
- 2015-05-21 TW TW104116291A patent/TW201625641A/zh unknown
- 2015-05-22 KR KR1020167035746A patent/KR20170005865A/ko unknown
- 2015-05-22 CN CN201580039570.4A patent/CN106661044B/zh active Active
- 2015-05-22 SG SG10201810263QA patent/SG10201810263QA/en unknown
- 2015-05-22 SG SG11201609615UA patent/SG11201609615UA/en unknown
- 2015-05-22 MX MX2016015298A patent/MX2016015298A/es unknown
- 2015-05-22 EP EP15727798.9A patent/EP3145933B1/en active Active
- 2015-05-22 RU RU2016150395A patent/RU2016150395A/ru not_active Application Discontinuation
- 2015-05-22 JP JP2016568840A patent/JP6580597B2/ja active Active
- 2015-05-22 AU AU2015263980A patent/AU2015263980A1/en not_active Abandoned
- 2015-05-22 US US15/312,482 patent/US10017523B2/en active Active
- 2015-05-22 CA CA2948878A patent/CA2948878A1/en not_active Abandoned
- 2015-05-22 BR BR112016026905A patent/BR112016026905A8/pt not_active IP Right Cessation
- 2015-05-22 AR ARP150101612A patent/AR100588A1/es unknown
- 2015-05-22 WO PCT/US2015/032170 patent/WO2015179759A1/en active Application Filing
-
2016
- 2016-11-21 IL IL249086A patent/IL249086A0/en unknown
-
2018
- 2018-07-03 US US16/026,901 patent/US20180312525A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20180312525A1 (en) | 2018-11-01 |
CN106661044A (zh) | 2017-05-10 |
MX2016015298A (es) | 2017-03-23 |
AU2015263980A1 (en) | 2018-08-16 |
CA2948878A1 (en) | 2015-11-26 |
JP2017516774A (ja) | 2017-06-22 |
AR100588A1 (es) | 2016-10-19 |
CN106661044B (zh) | 2019-03-22 |
BR112016026905A8 (pt) | 2021-07-20 |
RU2016150395A3 (zh) | 2019-01-16 |
KR20170005865A (ko) | 2017-01-16 |
US10017523B2 (en) | 2018-07-10 |
BR112016026905A2 (pt) | 2017-08-15 |
EP3145933A1 (en) | 2017-03-29 |
WO2015179759A1 (en) | 2015-11-26 |
RU2016150395A (ru) | 2018-06-25 |
SG11201609615UA (en) | 2016-12-29 |
US20170107231A1 (en) | 2017-04-20 |
EP3145933B1 (en) | 2021-03-17 |
IL249086A0 (en) | 2017-01-31 |
TW201625641A (zh) | 2016-07-16 |
JP6580597B2 (ja) | 2019-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201809518QA (en) | Processes of preparing a jak1 inhibitor and new forms thereto | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
MX2020001278A (es) | Sintesis de compuestos de carbamoilpiridona policiclica. | |
PH12017501523A1 (en) | Selective bace1 inhibitors | |
TW201613859A (en) | Analogs of PRIDOPIDINE, their preparation and use | |
PH12015502248B1 (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors | |
JO3466B1 (ar) | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 | |
MX2018001699A (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1. | |
JO3719B1 (ar) | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 | |
PH12016501941A1 (en) | Use of heterocyclic compounds for controlling nematodes | |
PH12016501613B1 (en) | Pyrazines modulators of gpr6 | |
MX2016013981A (es) | Derivados de amino-piridina como inhibidores de fosfatidil-inositol-3-cinasa. | |
MX2018003903A (es) | Compuesto biciclico y uso del mismo para inhibicion de suv39h2. | |
PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
SG10201810263QA (en) | Nampt inhibitors and methods | |
MX2019002017A (es) | Derivados de sofosbuvir para el tratamiento de la hepatitis c. | |
WO2018075598A8 (en) | SYNTHESIS OF EZH2 INHIBITORS | |
PH12017500492A1 (en) | Crystalline bace inhibitors | |
MX2017008655A (es) | Derivados de jasmonato y composiciones de los mismos. | |
IN2014MU00072A (zh) |